Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Stage Information for Prostate Cancer
Staging TestsMost men are diagnosed with prostate cancer at an early clinical stage and do not have detectable metastases. Therefore, they generally do not have to undergo staging tests, such as a bone scan, computed tomography (CT), or magnetic resonance imaging (MRI). However, staging studies are done if there is clinical suspicion of metastasis, such as bone pain; local tumor spread beyond the prostate capsule; or a substantial risk of metastasis (prostate-specific antigen [PSA] >20 ng/ml and Gleason score >7).Tests used to determine stage include the following:Radionuclide bone scans.Serum PSA level.MRI.Pelvic lymph node dissection (PLND).Transrectal or transperineal biopsy.Transrectal ultrasound (TRUS).CT scans.Radionuclide bone scansA radionuclide bone scan is the most widely used test for metastasis to the bone, which is the most common site of distant
Prostate Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Prostate Cancer, Advanced or Metastatic - Changes to This Summary (08 / 22 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.
Prostate Cancer, Advanced or Metastatic - Pomegranate
OverviewThis section contains the following key information:The pomegranate (Punica granatum L.) is native to Asia and cultivated widely throughout world.Various components of the pomegranate fruit contain bioactive compounds, including catechin phenolics, related flavonoids, and anthocyanins, some of which have antioxidant activity.Pomegranate juice and extract, as well as some of their bioactive components, inhibit the proliferation of various prostate cancer cell lines in vitro and induce apoptotic cell death in a dose-dependent manner.Cytochrome P450 enzyme inhibition and effects on insulin-like growth factor binding protein -3 (IGFBP-3) have been identified as being involved in the in vitro anticancer activity.Studies in rodent models of prostate cancer have shown that ingestion of pomegranate juice can decrease the rate of development, growth, and spread of prostate cancer.The only fully reported clinical trial of the use of pomegranate juice in men with prostate
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Prostate Cancer Treatment
OverviewIn recurrent prostate cancer, the selection of further treatment depends on many factors, including:Previous treatment.Site of recurrence.Coexistent illnesses.Individual patient considerations. Definitive radiation therapy can be given to patients with disease that fails only locally following prostatectomy.[1,2,3,4] An occasional patient can be salvaged with prostatectomy after a local recurrence following definitive radiation therapy; however, only about 10% of patients treated initially with radiation therapy will have local relapse only. In these patients, prolonged disease control is often possible with hormonal therapy, with median cancer-specific survival of 6 years after local failure.Cryosurgical ablation of recurrence following radiation therapy is associated frequently with a high complication rate. This technique is still undergoing clinical evaluation.Hormonal therapy is used to manage most relapsing patients with
Prostate Cancer, Advanced or Metastatic - nci_ncicdr0000719335-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Prostate Cancer, Nutrition, and Dietary Supplements
Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - What is prevention?
WebMD discusses methods of preventing prostate cancer.
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions and Answers About Zyflamend
Complementary and alternative medicine (CAM)—also referred to as integrative medicine—includes a broad range of healing philosophies, approaches, and therapies. A therapy is generally called complementary when it is used in addition to conventional treatments; it is often called alternative when it is used instead of conventional treatment. (Conventional treatments are those that are widely accepted and practiced by the mainstream medical community.) Depending on how they are used, some therapies can be considered either complementary or alternative. Complementary and alternative therapies are used in an effort to prevent illness, reduce stress, prevent or reduce side effects and symptoms, or control or cure disease. Unlike conventional treatments for cancer, complementary and alternative therapies are often not covered by insurance companies. Patients should check with their insurance provider to find out about coverage for complementary and alternative therapies. Cancer patients
Prostate Cancer, Advanced or Metastatic - Overview of CAM Use in Prostate Cancer
Studies of CAM use to treat prostate cancer have shown the following:Men who have prostate cancer are more likely to take dietary supplements than men who do not have prostate cancer.Prostate cancer patients with the healthiest eating habits (for example, eating lots of fish rich in omega-3 fatty acids and vegetables) are the most likely to take dietary supplements.Popular dietary supplements used by prostate cancer patients include lycopene, vitamin E, selenium, and saw palmetto.Reasons given by prostate cancer patients for using CAM treatments include boosting the immune system, improving quality of life, and lowering the risk of the cancer coming back.Studies of CAM use to lower the risk of developing prostate cancer or to prevent it from coming back have shown the following:A study of men with a family history of prostate cancer found that over half used vitamins or other dietary supplements, including those sold for prostate health or cancer prevention such as selenium, green
Prostate Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Evidence of Benefit
Before the 1990s, the digital rectal examination (DRE) was the test traditionally used for prostate cancer screening. Two other procedures are also available: transrectal ultrasound (TRUS) imaging and serum prostate-specific antigen (PSA) concentrations. Prostate cancer screening is controversial because of the lack of definitive evidence of benefit. A small randomized trial in Sweden evaluated the effects of screening men aged 50 to 69 years every 3 years; the first two screenings included DRE only, followed by two screenings with DRE combined with a test for PSA. The trial was not powered to detect even moderate differences in prostate cancer mortality, which was the same in the two groups: 1.3% (20 of 1,494 patients) for men assigned to screening and 1.3% (97 of 7,532 patients) for controls. The controversy persists. A nested case-control study was conducted at ten U.S. Department of Veterans